ADMA Biologics Inc (NASDAQ:ADMA) Position Trimmed by Roman Butler Fullerton & Co.

Roman Butler Fullerton & Co. trimmed its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 34.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 61,591 shares of the biotechnology company’s stock after selling 32,168 shares during the period. Roman Butler Fullerton & Co.’s holdings in ADMA Biologics were worth $1,222,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in ADMA Biologics by 1.3% during the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,466 shares of the biotechnology company’s stock worth $865,000 after buying an additional 645 shares during the last quarter. Oregon Public Employees Retirement Fund boosted its holdings in shares of ADMA Biologics by 1.3% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company’s stock valued at $954,000 after acquiring an additional 700 shares during the period. Summit Investment Advisors Inc. grew its position in shares of ADMA Biologics by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 23,560 shares of the biotechnology company’s stock worth $404,000 after acquiring an additional 746 shares during the last quarter. Mutual of America Capital Management LLC boosted its stake in ADMA Biologics by 2.1% during the 4th quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company’s stock valued at $614,000 after purchasing an additional 751 shares during the period. Finally, Maryland State Retirement & Pension System grew its position in ADMA Biologics by 1.1% in the 4th quarter. Maryland State Retirement & Pension System now owns 79,607 shares of the biotechnology company’s stock worth $1,365,000 after purchasing an additional 897 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 price objective on shares of ADMA Biologics in a research report on Tuesday, March 4th. Wall Street Zen downgraded ADMA Biologics from a “hold” rating to a “sell” rating in a research note on Friday, May 9th. Finally, Raymond James Financial increased their price target on ADMA Biologics from $25.00 to $32.00 and gave the stock a “strong-buy” rating in a research note on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $24.25.

Insider Buying and Selling at ADMA Biologics

In other news, Director Lawrence P. Guiheen sold 20,000 shares of the stock in a transaction on Monday, June 9th. The stock was sold at an average price of $20.96, for a total value of $419,200.00. Following the completion of the sale, the director now owns 94,830 shares in the company, valued at $1,987,636.80. This represents a 17.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jerrold B. Grossman sold 10,000 shares of ADMA Biologics stock in a transaction on Monday, June 9th. The shares were sold at an average price of $21.31, for a total value of $213,100.00. Following the transaction, the director now owns 478,194 shares in the company, valued at $10,190,314.14. This represents a 2.05% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 464,621 shares of company stock valued at $9,644,269. 3.70% of the stock is owned by insiders.

ADMA Biologics Trading Down 7.4%

Shares of NASDAQ:ADMA opened at $18.89 on Wednesday. The company has a 50 day moving average of $20.98 and a 200-day moving average of $18.83. The company has a current ratio of 6.58, a quick ratio of 3.36 and a debt-to-equity ratio of 0.22. The firm has a market cap of $4.51 billion, a P/E ratio of 22.22 and a beta of 0.47. ADMA Biologics Inc has a twelve month low of $10.21 and a twelve month high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.02). The firm had revenue of $114.80 million for the quarter, compared to the consensus estimate of $116.40 million. ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. ADMA Biologics’s revenue for the quarter was up 40.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.08 EPS. As a group, analysts anticipate that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.